NE1

NE1 is developing MBRP-Vax, an autologous tumor cell-based vaccine intended to treat glioblastoma and prevent its recurrence; it co-owns patent rights on personalized tumor vaccines made from irradiated tumor cells pulsed with Mannan-BAM, TLR ligands and anti-CD40 antibody. Source

Keywords: MBRP-Vax autologous tumor cell-based vaccine glioblastoma personalized tumor vaccines Mannan-BAM